Japanese maker of Kampo (traditional herbal) medicines, the market leader in prescription herbal drugs.
Japanese maker of Kampo (traditional herbal) medicines, the market leader in prescription herbal drugs.
Its Kampo formulations are on Japan's national health insurance drug price list, so doctors prescribe them with the cost largely reimbursed, and the government sets the price and reviews it regularly. Most herbal raw material is imported, largely from China, so ingredient supply and cost matter.
In one line: No direct US analogue — a prescription herbal-medicine maker.
Moat: wide (regulatory licence, brand, scale). Dominant share and long regulatory/insurance approval history in Japan's unique Kampo drug category.
Headquarters: Kyoto, Japan · Founded: 1893 · Employees: 4,923
Size Tsumura & (4540.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 502nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,006 on 18 Nov 2026.
Performance Over six months the shares gained 6.0%, against -5.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +8.7%); the operating margin is 17.9% (peer median 20.9%).
Valuation It trades at 10.4× forward earnings against a peer median of 22.8× (3rd cheapest of 17).
Capital Return on invested capital runs 0.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥206B | ¥193B | ¥181B | ¥151B | ¥140B |
| Revenue growth | — | +6% | +20% | +8% | — |
| Gross profit | ¥96.7B | ¥91.5B | ¥90.6B | ¥68.8B | ¥68.3B |
| EBITDA | ¥51.6B | ¥48.3B | ¥51.3B | ¥30.8B | ¥31.5B |
| Net income | ¥31.8B | ¥28.1B | ¥32.4B | ¥16.7B | ¥16.5B |
| Free cash flow | -¥4.54B | -¥9.16B | ¥6.23B | -¥11.2B | ¥4.23B |
| Capital expenditure | ¥37.7B | ¥34.4B | ¥29.8B | ¥20.1B | ¥14.7B |
| Total debt | ¥153B | ¥136B | ¥70.8B | ¥80.1B | ¥80.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4540.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.9% | +0.3% | 8th highest of 21 |
| 6-month return | +6.0% | -5.5% | 8th highest of 21 |
| Distance from 52-week high | -9.0% | -28.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +13.3% | +8.7% | 6th highest of 20 |
| Operating margin | 17.9% | 20.9% | 10th lowest of 20 |
| Forward P/E | 10.4× | 22.8× | 3rd cheapest of 17 |
| ROIC minus cost of capital | +0.1 pp | +1.6 pp | 10th lowest of 20 |
| EV / EBITDA | 8.1× | 17.8× | 3rd cheapest of 10 |
| Net debt / EBITDA | 1.0× | 1.4× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |